The firm said that initial results from the study indicated that Dyadic’s C1 antigen showed strong performance in protecting cattle and mice from the devastating Schmallenberg virus, which causes congenital malformations in certain animals.
The positive news means ZAPI is expanding the scope of Dyadic’s involvement in the program, the firm said in a release.
Dyadic expects to get more funding from the ZAPI consortium to support the production of two additional targets. Final results from the study should be published in the second quarter of 2020, according to Dyadic CEO Mark Emalfarb.
The company is working on two additional proteins for the animal health market, Emalfarb told shareholders. It already has ongoing collaborations with two of the top four animal health companies.
Emalfarb shared the news as part of a wider business update that highlighted scientific results from a busy fourth quarter for the company.
Dyadic is expanding its research relationship with the microbial fermentation group of a major pharmaceutical company to evaluate C1 for their own internal use, the company said Monday. The nonexclusive license allows Dyadic’s collaborator to perform certain experiments and manipulations to the C1 cell lines to create potential licensed products, as well as other internal noncommercial purposes.
Emalfarb called the strengthened relationship an “exciting endorsement” of the potential of its C1 technology.
“Our ongoing fully funded research collaboration with this collaborator helped us to obtain a research license with another part of the global organization where we will tech transfer our C1 technology to their in-house lab for their scientists to further evaluate it, possibly improving upon it, with the objective of broadening and accelerating the adoption and use of C1 globally,” Emalfarb said.
The expanding business portfolio further highlights the significant runway for value creation at Dyadic, he added.
The collaborator will invest its own resources to evaluate C1 technology for their customers globally.
In a separate collaboration between Dyadic and the Israeli Institute of Biological Research (IIBR), a proprietary IIBR Fc-fusion enzyme has been expressed using C1 technology.
The Acetyl Choline Esterase enzyme has previously been shown to provide certain countermeasures against nerve agents such as sarin and VX gas which are toxic and rapidly acting chemical warfare agents, according to Dyadic. The recombinant IIBR Fc-fusion enzyme provides longer protection than the common Acetyl Choline Esterase, the firm said.
"This collaboration with IIBR demonstrates a new class of proteins that can be expressed from C1 to produce larger amounts of lower cost countermeasures for chemical and biological threats globally,” Emalfarb said in a statement.
Additional highlights come from the firm’s glycoengineering program that demonstrated the potential applicability of the C1 technology for developing and manufacturing types of biosimilar, biobetters and new biomolecules.
Emalfarb said that Dyadic should be able to develop and manufacture biopharmaceuticals for certain diseases, including cancer and arthritis, in large volumes at lower cost.
Also in 4Q, Dyadic partnered with a top ten pharmaceutical company and filed two additional patent applications.
Dyadic will be attending the JP Morgan conference in San Francisco on January 12 and 13 to discuss the company’s progress.
Contact Angela at [email protected]
Follow her on Twitter @AHarmantas